TY - JOUR
T1 - Adverse Events of Intense Pulsed Light Combined With Meibomian Gland Expression Versus Meibomian Gland Expression in the Treatment of Meibomian Gland Dysfunction
AU - Qiao, Chen
AU - Li, Liping
AU - Wang, Haoyu
AU - Zhao, Cong
AU - Ke, Lan
AU - Sen, Dan
AU - Qi, Mengying
AU - Li, Shaowei
AU - Wang, Mingwu
AU - Zeng, Qingyan
N1 - Funding Information:
Contract grant sponsor: Youth Projects of Health and Family Planning Commission of Wuhan Municipality; Contract grant number: WX18Q46; Contract grant sponsor: Projects of Aier Eye Group; Contract grant number: AR1904D2.
Funding Information:
The study was supported by Youth Projects of Health and Family Planning Commission of Wuhan Municipality (WX18Q46) and Projects of Aier Eye Group (AR1904D2).
Publisher Copyright:
© 2020 Wiley Periodicals LLC
PY - 2021/7
Y1 - 2021/7
N2 - Background and Objective: To analyze the occurrence and causes of adverse events (AEs) in intense pulsed light (IPL) combined with meibomian gland expression (MGX) and MGX treatment alone for meibomian gland dysfunction (MGD). Study Design/Materials and Methods: A retrospective study was conducted on MGD patients treated in Wuhan Aier Hankou Eye Hospital from February 2018 to October 2019 to compare the AEs between IPL-MGX and MGX groups. Relevant AEs that occurred during the treatment and within 1 month after the patients' last treatment were recorded and the causes of the AEs were analyzed. Results: A total of 2,282 patients received IPL-MGX and 1,407 received MGX treatment. No serious AEs occurred in both groups. There were 74 AEs in the IPL-MGX group, with an incidence of 3.24%, including 14 significant AEs (2 cases of epidemic keratoconjunctivitis, 1 recurrent herpes simplex keratitis (HSK), 9 new onsets of floaters, 1 recurrent glaucomatocyclitic crises, and 1 recurrent iridocyclitis). There were 27 AEs in the MGX group with a rate of 1.92%, including 4 significant AEs (2 cases of keratoconjunctivitis epidemic, 2 new cases of floaters). Compared with the IPL-MGX group, the incidence of AEs in the MGX group was lower (P = 0.017). Conclusions: Both IPL-MGX and MGX treatment are safe therapies with low risk for AEs. IPL treatment is not recommended for young children (age 10 or less) as well as patients with anterior uveitis or glaucomatocyclitic crises. The previous history of HSK and eyes with high myopia are advised to exercise caution in IPL treatment. Lasers Surg. Med.
AB - Background and Objective: To analyze the occurrence and causes of adverse events (AEs) in intense pulsed light (IPL) combined with meibomian gland expression (MGX) and MGX treatment alone for meibomian gland dysfunction (MGD). Study Design/Materials and Methods: A retrospective study was conducted on MGD patients treated in Wuhan Aier Hankou Eye Hospital from February 2018 to October 2019 to compare the AEs between IPL-MGX and MGX groups. Relevant AEs that occurred during the treatment and within 1 month after the patients' last treatment were recorded and the causes of the AEs were analyzed. Results: A total of 2,282 patients received IPL-MGX and 1,407 received MGX treatment. No serious AEs occurred in both groups. There were 74 AEs in the IPL-MGX group, with an incidence of 3.24%, including 14 significant AEs (2 cases of epidemic keratoconjunctivitis, 1 recurrent herpes simplex keratitis (HSK), 9 new onsets of floaters, 1 recurrent glaucomatocyclitic crises, and 1 recurrent iridocyclitis). There were 27 AEs in the MGX group with a rate of 1.92%, including 4 significant AEs (2 cases of keratoconjunctivitis epidemic, 2 new cases of floaters). Compared with the IPL-MGX group, the incidence of AEs in the MGX group was lower (P = 0.017). Conclusions: Both IPL-MGX and MGX treatment are safe therapies with low risk for AEs. IPL treatment is not recommended for young children (age 10 or less) as well as patients with anterior uveitis or glaucomatocyclitic crises. The previous history of HSK and eyes with high myopia are advised to exercise caution in IPL treatment. Lasers Surg. Med.
KW - adverse event
KW - intense pulsed light
KW - meibomian gland dysfunction
KW - meibomian gland expression
UR - http://www.scopus.com/inward/record.url?scp=85096793371&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096793371&partnerID=8YFLogxK
U2 - 10.1002/lsm.23339
DO - 10.1002/lsm.23339
M3 - Article
C2 - 33161597
AN - SCOPUS:85096793371
SN - 0196-8092
VL - 53
SP - 664
EP - 670
JO - Lasers in Surgery and Medicine
JF - Lasers in Surgery and Medicine
IS - 5
ER -